C529-0730 Screening compound: 10-(2-fluorobenzyl)-5,11-dioxo-N~8~-(tetrahydro-2-furanylmethyl)-10,11-dihydro-5H-5lambda~4~-dibenzo[b,f][1,4]thiazepine-8-carboxamide

C529-0730 Screening compound: 10-(2-fluorobenzyl)-5,11-dioxo-N~8~-(tetrahydro-2-furanylmethyl)-10,11-dihydro-5H-5lambda~4~-dibenzo[b,f][1,4]thiazepine-8-carboxamide
C529-0730 Screening compound: 10-(2-fluorobenzyl)-5,11-dioxo-N~8~-(tetrahydro-2-furanylmethyl)-10,11-dihydro-5H-5lambda~4~-dibenzo[b,f][1,4]thiazepine-8-carboxamide alternative view

Chemical Structure Depiction of ChemDiv screening compound C529-0730
10-(2-fluorobenzyl)-5,11-dioxo-N~8~-(tetrahydro-2-furanylmethyl)-10,11-dihydro-5H-5lambda~4~-dibenzo[b,f][1,4]thiazepine-8-carboxamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

C529-0730

Molecular Formula

C26H23FN2O4S (C26 H23 FN2 O4 S)

Compound Name

10-(2-fluorobenzyl)-5,11-dioxo-N~8~-(tetrahydro-2-furanylmethyl)-10,11-dihydro-5H-5lambda~4~-dibenzo[b,f][1,4]thiazepine-8-carboxamide

IUPAC name

9-[(2-fluorophenyl)methyl]-210-dioxo-N-[(oxolan-2-yl)methyl]-2lambda4-thia-9-azatricyclo[9.4.0.0^{38}]pentadeca-1(11)3(8)461214-hexaene-6-carboxamide

SMILES

O=C(c(cc1)cc(N(Cc(cccc2)c2F)C(c2c3cccc2)=O)c1S3=O)NCC1OCCC1

InChI

InChI=1S/C26H25FN2O4S/c27-21-9-3-1-6-18(21)16-29-22-14-17(25(30)28-15-19-7-5-13-33-19)11-12-24(22)34(32)23-10-4-2-8-20(23)26(29)31/h1-4,6,8-12,14,19H,5,7,13,15-16,34H2,(H,28,30)

InChI Key

VIYJREJLLLWHMW-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD14767356

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

478.54

Hydrogen Bond Acceptors Count

8.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

6.00

Number of Nitrogen and Oxygen Atoms

6

Partition Coefficient, logP

2.796

Distribution Coefficient, logD

2.796

Water Solubility, LogSw

-3.73

Polar Surface Area

63.852

Acid Dissociation Constant (pKa)

13.58

Base Dissociation Constant (pKb)

-2.49

Number of Chiral Centers

1.00

Percent sp3 carbon bonding

23.10

C529-0730 in Drug Discovery

Included in Screening Libraries

Allosteric Kinases Inhibitors Library (23117 compounds)

Antiviral Library (67538 compounds)

Protein-Protein Interaction Library (218420 compounds)

Adenosine Receptors Targeted Library (19896 compounds)

Recognition Elements PPI Library (24135 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Female
  • Congenital
  • Skin
  • Antiviral
  • Infections
  • Immune system
  • Cancer
  • Digestive system
  • Respiratory tract
  • Nervous system
  • Eye
  • Cardiovascular
Targets:
  • Kinases
  • GPCR
Mechanism of action:
  • PPI modulators
  • Receptor's ligands
  • PPI modulators
Structure:
  • Mimetics

References: we are preparing a list of scientific research reports with C529-0730 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound C529-0730?
Check Price and Availability of C529-0730, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of C529-0730 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for C529-0730
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for C529-0730
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of C529-0730 available by request